ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection

• Proceeds will support continued commercial expansion, operational scale-up, clinical study execution, and product development
• Clinical oncology diagnostics veteran Kevin Keegan appointed president and chief operating officer

SAN DIEGO--(BUSINESS WIRE)--ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, today announced the close of $52 million in Series D financing, along with the appointment of industry veteran Kevin Keegan as president and chief operating officer. The financing and leadership expansion position ClearNote Health to accelerate growth amid increasing demand for more accurate, accessible, and affordable noninvasive tools for early cancer detection.

With this Series D financing, the company has received total funding of more than $185 million from leading institutional investors. The round was led by founding investor Mattias Westman and a global, large, long-only active manager. Other participants included former CEO and chairman of Citigroup Sandy Weill, ClearNote Health co-founder Dr. Stephen Quake of Stanford University, a large Seattle-based family office, and other U.S. and international-based institutional investors. Proceeds from the financing will support continued commercial expansion, clinical study execution, product development, and broader global access to ClearNote Health’s portfolio of Avantect® early cancer detection tests and Virtuoso™ epigenomic drug development platform.

“I invested early because I believed ClearNote Health was tackling one of the most important challenges in healthcare,” said Mr. Westman. “The potential to detect cancer earlier through epigenomic signals in blood is incredibly compelling, and the team has continued to execute with focus, scientific rigor, and a real sense of purpose. The progress they’ve made so far has only strengthened my belief in what the company can achieve.”

“This Series D financing validates our strong commercial momentum and differentiated platform, as well as the tremendous market opportunity in early cancer detection,” said Dave Mullarkey, CEO of ClearNote Health. “We are also thrilled to welcome Kevin, a proven industry leader with deep expertise in molecular diagnostics and oncology. His operational and commercial leadership will be instrumental as we scale our organization, expand globally, and increase access to our portfolio of early cancer detection tests for patients at elevated risk.”

Mr. Keegan brings nearly 30 years of experience in the clinical diagnostics industry, spanning operational, commercial, and general management roles. Prior to joining ClearNote Health, he held senior leadership positions at BD, Illumina, and Hologic. At Illumina, he served as general manager of oncology, where he led the launch of one of the world’s most widely used tumor profiling tests.

“During my career, I have focused on expanding access to genomics-based oncology diagnostic tools,” said Mr. Keegan. “ClearNote Health has a purpose-built platform that has the potential to fundamentally improve outcomes for patients at elevated risk of cancer by diagnosing disease earlier. I’m excited to join this talented team and to help drive the company’s next growth phase.”

ClearNote Health’s leadership expansion occurs as the company builds on the recent success of its enhanced Avantect Pancreatic Cancer Test. Designed as a simple blood-based test, the ClearNote Avantect tests feature an integrated, multiomic approach with optimized machine learning algorithms. With their high overall cancer detection sensitivity and specificity, Avantect tests help clinicians to identify early-stage cancers sooner, enabling more informed and timely clinical management decisions.¹

To learn more about the Avantect cancer tests, visit www.avantect.com.

About ClearNote Health

ClearNote Health is a privately held company dedicated to improving early detection and monitoring for some of the deadliest forms of cancer. Developed by scientists in the Stephen Quake laboratory at Stanford University, the company’s patented Virtuoso™ epigenomics platform builds on the latest advances in artificial intelligence and bioinformatics to measure active biological differences between cancer and healthy cells in a blood sample. The highly sensitive, noninvasive Avantect® pancreatic and ovarian tests may identify cancers in high-risk patient populations earlier than conventional approaches, when patients may be more likely to benefit from treatment. The company’s multi-cancer detection test was recently selected as one of two blood-based technologies for the National Cancer Institute’s Vanguard Study. ClearNote Health’s headquarters and CLIA-certified, CAP-accredited, and New York State Department of Health-approved laboratory are located in San Diego. For more information, visit www.clearnotehealth.com or follow the company on LinkedIn.

References

¹ Bergamaschi A, et al. Enhanced early detection of pancreatic cancer using a multi-analyte liquid biopsy approach. Cancer Research. 2026;86(7_Supplement):4075. Presented at: AACR Annual Meeting 2026. doi:10.1158/1538-7445.AM2026-4075.

ClearNote Health, the ClearNote Health logo, and Avantect are registered trademarks of ClearNote Health.